Dr Charles Mullighan speaks to ecancer at the 2020 ALL Assembly meeting in Frankfurt about the treatment landscape of B-progenitor acute lymphoblastic leukaemia (B-ALL), including the use of novel approaches.

He describes the challenges of treating Ph-like acute lymphoblastic leukaemia (ALL), in which patients with the CRF2-rearranged subtype respond poorly to the JAK/STAT inhibitor ruxolitinib.

To target this subtype differently, Dr Mullighan explores the effectiveness of using targeted protein degradation to directly inhibit the JAK/STAT signalling pathway.

He also discusses the mechanisms of resistance to blinatumomab, which is a widely used agent that is increasingly used in the front-line.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

свернуть